Literature DB >> 12841387

Prognostic significance of CD7+CD56+ phenotype and chromosome 5 abnormalities for acute myeloid leukemia M0.

Ritsuro Suzuki1, Makoto Murata, Masahiro Kami, Shigeki Ohtake, Norio Asou, Yoshihisa Kodera, Masao Tomonaga, Yasufumi Masaki, Shuya Kusumoto, Jin Takeuchi, Shin Matsuda, Hisamaru Hirai, m Seiichi Yorimitsu, Nobuyuki Hamajima, Masao Seto, Masanori Shimoyama, Ryuzo Ohno, Yasuo Morishima, Shigeo Nakamura.   

Abstract

Myeloid/natural killer (NK) cell precursor acute leukemia is an entity of acute leukemia characterized by poor prognosis and a CD7+CD56+ myeloid antigen+ phenotype without light-microscopic myeloperoxidase reactivity. This disease shares several clinical characteristics with acute myeloid leukemia (AML) M0. To clarify the relationship between these 2 leukemias, we analyzed 105 cases of AML M0. Among them, 17 were CD7+ and CD56+, 77 were negative for either antigen, and 11 could not be determined. CD7+CD56+ AML M0 showed onset at significantly lower patient age (median 46 versus 63 years, P = .004). The disease localization and the hematological manifestations were significantly different: CD7+CD56+ AML showed more frequent extramedullary involvement, fewer circulating leukemic blasts, less anemia, and less thrombocytopenia than did AML M0. The cytogenetic aberrations were also unique, because no 5q abnormalities were found in CD7+CD56+ M0. The prognosis of CD7+CD56+ M0 was poor in patients younger than 46 years (P = .03). Multivariate analysis showed that the CD7+CD56+ phenotype was a significant prognostic factor for AML M0, as well as age, circulating blast percentage, and chromosome 5 abnormalities These findings suggest that AML M0 consists of heterogeneous subgroups to be managed separately, and CD7+CD56+ M0 constitutes a distinct subtype of AML M0.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12841387     DOI: 10.1007/bf02986617

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  51 in total

1.  Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.

Authors:  R Suzuki; Y Kagami; K Takeuchi; M Kami; M Okamoto; R Ichinohasama; N Mori; M Kojima; T Yoshino; H Yamabe; M Shiota; S Mori; M Ogura; N Hamajima; M Seto; T Suchi; Y Morishima; S Nakamura
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

2.  Limitations of the diagnostic criteria for minimally differentiated acute myeloid leukemia (AML-MO)

Authors:  H Iwata; M Kami; Y Kishi; Y Oki; Y Tanaka; K Takeuchi; I Yamazaki; R Suzuki; S Morinaga; Y Mutou
Journal:  Leukemia       Date:  2000-11       Impact factor: 11.528

3.  CD7+ and CD56+ myeloid/natural killer cell precursor acute leukemia treated with idarubicin and cytosine arabinoside.

Authors:  Hiroshi Handa; Sachiko Motohashi; Kazuo Isozumi; Satoru Komatsumoto; Masaharu Nara
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

4.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO)

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Br J Haematol       Date:  1991-07       Impact factor: 6.998

5.  Clinicopathological features of myeloid/natural killer (NK) cell precursor acute leukemia.

Authors:  T Inaba; C Shimazaki; T Sumikuma; N Ochiai; A Okano; M Hatsuse; E Ashihara; Y Kobayashi; K Rin; S Murakami; H Haruyama; N Fujita; M Nakagawa
Journal:  Leuk Res       Date:  2001-02       Impact factor: 3.156

6.  Minimally differentiated acute leukemia.

Authors:  F J Cadwell; C P Burns; F R Dick; M P Jones; K D Heckman; G J Weiner; J A Goeken
Journal:  Leuk Res       Date:  1993-03       Impact factor: 3.156

7.  Criteria for the diagnosis of acute leukemia of megakaryocyte lineage (M7). A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-09       Impact factor: 25.391

8.  Aggressive natural killer cell leukemia in an adult with establishment of an NK cell line.

Authors:  L A Fernandez; B Pope; C Lee; E Zayed
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

9.  Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics.

Authors:  N Villamor; M A Zarco; M Rozman; J M Ribera; E Feliu; E Montserrat
Journal:  Leukemia       Date:  1998-07       Impact factor: 11.528

10.  Treatment of a child with myeloid/NK cell precursor acute leukemia with L-asparaginase and unrelated cord blood transplantation.

Authors:  Kayo Tezuka; Hideki Nakayama; Keiko Honda; Junji Suzumiya; Kouichi Oshima; Toshiyuki Kitoh; Eiichi Ishii
Journal:  Int J Hematol       Date:  2002-02       Impact factor: 2.319

View more
  5 in total

1.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.

Authors:  Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Harald Rieder; Monika Brüggemann; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

2.  The clinical characteristics of CD7+ CD56+ acute myeloid leukemias other than M0.

Authors:  Ritsuro Suzuki; Shigeki Ohtake; Jin Takeuchi; Masami Nagai; Yoshihisa Kodera; Motohiro Hamaguchi; Shuichi Miyawaki; Takahiro Karasuno; Shigetaka Shimodaira; Ryuzo Ohno; Shigeo Nakamura; Tomoki Naoe
Journal:  Int J Hematol       Date:  2010-01-29       Impact factor: 2.490

3.  CD56/NCAM-positive Langerhans cell sarcoma: a clinicopathologic study of 4 cases.

Authors:  Takakazu Kawase; Minoru Hamazaki; Michinori Ogura; Yoshiaki Kawase; Toshihiko Murayama; Yoshio Mori; Hirokazu Nagai; Masatoshi Tateno; Takashi Oyama; Yoshikazu Kamiya; Hirofumi Taji; Yoshitoyo Kagami; Tomoki Naoe; Toshitada Takahashi; Yasuo Morishima; Shigeo Nakamura
Journal:  Int J Hematol       Date:  2005-05       Impact factor: 2.490

4.  Two entities of precursor T-cell lymphoblastic leukemia/lymphoma based on radiologic and immunophenotypic findings.

Authors:  Yasushi Onishi; Yoshihiro Matsuno; Ukihide Tateishi; Akiko Miyagi Maeshima; Masahiko Kusumoto; Takashi Terauchi; Shigeru Kusumoto; Naohiro Sekiguchi; Kazuki Tanimoto; Takashi Watanabe; Yukio Kobayashi; Kensei Tobinai
Journal:  Int J Hematol       Date:  2004-07       Impact factor: 2.490

Review 5.  Leukemia and lymphoma of natural killer lineage cells.

Authors:  Kazuo Oshimi
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.